Cantor Fitzgerald Reiterates Overweight on Ocular Therapeutix (OCUL) Following 1Q
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- S&P Global shares rise on report of possible CapIQ spinoff
Ocular Therapeutix™ Reports First Quarter 2018 Financial Results and Business Update
May 8, 2018 4:01 PM EDTTargeting DEXTENZA NDA Resubmission in the Second Quarter of 2018
BEDFORD, Mass.--(BUSINESS WIRE)-- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the first quarter ended March 31, 2018 and provided a business update.
We entered 2018 with an exciting set of opportunities that include a number of regulatory and clinical milestones, said Antony Mattessich, President and Chief Executive Officer. With the right strategy, objectives and leadership in... More
